These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1. Sullivan DJ; Franchini M; Senefeld JW; Joyner MJ; Casadevall A; Focosi D bioRxiv; 2022 Dec; ():. PubMed ID: 36482971 [TBL] [Abstract][Full Text] [Related]
44. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668 [TBL] [Abstract][Full Text] [Related]
45. Design of a chimeric ACE-2/Fc-silent fusion protein with ultrahigh affinity and neutralizing capacity for SARS-CoV-2 variants. Bodie NM; Hashimoto R; Connolly D; Chu J; Takayama K; Uhal BD Antib Ther; 2023 Jan; 6(1):59-74. PubMed ID: 36741194 [TBL] [Abstract][Full Text] [Related]
46. Pandemic COVID-19, an update of current status and new therapeutic strategies. Vitiello A; La Porta R; Trama U; Ferrara F; Zovi A; Auti AM; Di Domenico M; Boccellino M Naunyn Schmiedebergs Arch Pharmacol; 2022 Oct; 395(10):1159-1165. PubMed ID: 35779085 [TBL] [Abstract][Full Text] [Related]
47. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Uraki R; Kiso M; Iida S; Imai M; Takashita E; Kuroda M; Halfmann PJ; Loeber S; Maemura T; Yamayoshi S; Fujisaki S; Wang Z; Ito M; Ujie M; Iwatsuki-Horimoto K; Furusawa Y; Wright R; Chong Z; Ozono S; Yasuhara A; Ueki H; Sakai-Tagawa Y; Li R; Liu Y; Larson D; Koga M; Tsutsumi T; Adachi E; Saito M; Yamamoto S; Hagihara M; Mitamura K; Sato T; Hojo M; Hattori SI; Maeda K; Valdez R; ; Okuda M; Murakami J; Duong C; Godbole S; Douek DC; Maeda K; Watanabe S; Gordon A; Ohmagari N; Yotsuyanagi H; Diamond MS; Hasegawa H; Mitsuya H; Suzuki T; Kawaoka Y Nature; 2022 Jul; 607(7917):119-127. PubMed ID: 35576972 [TBL] [Abstract][Full Text] [Related]
48. Therapeutic potential of green tea catechin, (-)-epigallocatechin-3- Dinda B; Dinda S; Dinda M Phytomed Plus; 2023 Feb; 3(1):100402. PubMed ID: 36597465 [TBL] [Abstract][Full Text] [Related]
49. Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2. Park JG; Oladunni FS; Chiem K; Ye C; Pipenbrink M; Moran T; Walter MR; Kobie J; Martinez-Sobrido L J Virol Methods; 2021 Jan; 287():113995. PubMed ID: 33068703 [TBL] [Abstract][Full Text] [Related]
50. A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies. Chatterjee S; Bhattacharya M; Nag S; Dhama K; Chakraborty C Viruses; 2023 Jan; 15(1):. PubMed ID: 36680207 [TBL] [Abstract][Full Text] [Related]
51. Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections. Medits I; Springer DN; Graninger M; Camp JV; Höltl E; Aberle SW; Traugott MT; Hoepler W; Deutsch J; Lammel O; Borsodi C; Puchhammer-Stöckl E; Zoufaly A; Weseslindtner L; Aberle JH; Stiasny K Front Immunol; 2022; 13():946318. PubMed ID: 35928813 [TBL] [Abstract][Full Text] [Related]
52. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Kurhade C; Zou J; Xia H; Liu M; Chang HC; Ren P; Xie X; Shi PY Nat Med; 2023 Feb; 29(2):344-347. PubMed ID: 36473500 [TBL] [Abstract][Full Text] [Related]
53. Comparison of the replication and neutralization of different SARS-CoV-2 Omicron subvariants in vitro. Zhang Y; Lv Q; Qi F; Li F; Deng R; Liang X; Liu M; Yan Y; Bao L Animal Model Exp Med; 2023 Feb; 6(1):51-56. PubMed ID: 36808904 [TBL] [Abstract][Full Text] [Related]
54. The MEK1/2 Inhibitor ATR-002 (Zapnometinib) Synergistically Potentiates the Antiviral Effect of Direct-Acting Anti-SARS-CoV-2 Drugs. Schreiber A; Ambrosy B; Planz O; Schloer S; Rescher U; Ludwig S Pharmaceutics; 2022 Aug; 14(9):. PubMed ID: 36145524 [TBL] [Abstract][Full Text] [Related]
55. Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection. Kurhade C; Zou J; Xia H; Liu M; Yang Q; Cutler M; Cooper D; Muik A; Sahin U; Jansen KU; Ren P; Xie X; Swanson KA; Shi PY Emerg Microbes Infect; 2022 Dec; 11(1):1828-1832. PubMed ID: 35792746 [TBL] [Abstract][Full Text] [Related]
56. Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing. O'Shea KM; Schuler CF; Chen J; Troost JP; Wong PT; Chen K; O'Shea DR; Peng W; Gherasim C; Manthei DM; Valdez R; Baldwin JL; Baker JR Front Immunol; 2023; 14():1055429. PubMed ID: 36845123 [TBL] [Abstract][Full Text] [Related]
57. An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS-CoV-2. Zhang L; Narayanan KK; Cooper L; Chan KK; Skeeters SS; Devlin CA; Aguhob A; Shirley K; Rong L; Rehman J; Malik AB; Procko E EMBO Mol Med; 2022 Nov; 14(11):e16109. PubMed ID: 36094679 [TBL] [Abstract][Full Text] [Related]
58. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants. Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM Elife; 2022 Aug; 11():. PubMed ID: 36004719 [TBL] [Abstract][Full Text] [Related]
59. Viral target and metabolism-based rationale for combined use of recently authorized small molecule COVID-19 medicines: Molnupiravir, nirmatrelvir, and remdesivir. Yan D; Yan B Fundam Clin Pharmacol; 2023 Aug; 37(4):726-738. PubMed ID: 36931725 [TBL] [Abstract][Full Text] [Related]
60. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern. Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Stella AO; Kindinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Jean T; Foster CSP; Christ D; Hoppe AC; Munier ML; Darley D; Churchill M; Stark DJ; Matthews G; Rawlinson WD; Kelleher AD; Turville SG EBioMedicine; 2022 Oct; 84():104270. PubMed ID: 36130476 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]